| Objective:To observe the enema prescription No.1effect on diabetic nephropathy (DN)model of renal function in mice and TXNIP, CHOP gene expression.Methods:1Acute toxicity testing:20mice were randomly divided into blank controlgroup and enema prescription No.1group (10rats), control group was given normal saline0.8ml/20g,enema prescription No.1group, with the maximum concentration, with thelargest volume intragastrically administered enema prescription No.1extract suspension(the maximum concentration of1.3g/ml, the maximum administration volume0.8ml/20g)1.04g/20g, every8h administered once,2times in a row. Administration of theday,observation after administration of0h,2h,4h,6h, from the administration for seconddays beginning, every morning and the afternoon of the observation time,14days ofcontinuous observation. To observe the change of mice after administration of appearance,behavior, changes in the number of records, secretions, excretions, diet weight etc.2.Effect of enema prescription No.1on diabetic nephropathy in mice:68mice wererandomly divided into blank control group (group N), DN model group (group M), Beforethe establishment of the diabetic nephropathy model into medicine group (group YF),diabetic nephropathy after model administration group (D group), positive drug group(telmisartan group, T group, combination group (enema prescription No.1add Michatan,group TD), intraperitoneal injection of streptozotocin (STZ) to establish the mouse modelof DN.4weeks after drug intervention, by measuring the24h urine protein Coomassiebrilliant blue method; the automatic biochemical analyzer to measure serum creatinine(Scr), blood urea nitrogen (BUN); MASSON staining was used to measure the change ofrenal histopathological mice; thioredoxin used insulin reduction assay (TRX) activity wasdetected with Realtime-PCR method; kidney thioredoxin interacting protein (TXNIP),CHOP mRNA expression. Results:1Acute toxicity test: after administration of0h,2h,4h,6h, no abnormal reactionin blank control group, part of a number of mice enema decoction group appear burnoutdiscomfort, towering hair and other phenomena, the next morning to observe the recoveryof normal; observation of14days in a row, blank control group and enema prescriptionNo.1in both groups of mice there was no death; body weight compared with a number ofweight growth differences Party group and the blank control group (P>0.05); anatomicalobservation of the naked eye in normal MTD ratio of108times.2Effect of enemaprescription No.1on diabetic nephropathy in mice:Effect of enema prescription No.1onbody weight: compared with the blank control group, model group, body weight decreasedslightly, but the difference was not statistically significant (P>0.05), compared with themodel group, model group, administered before into the model after the administrationgroup, combination group (each medicine group) weight gain not significant (P>0.05);the effects on blood glucose: compared with the blank control group, diabetic model groupincreased significantly (P <0.05), compared with the model group, the blood glucoselevels to medicine group had no significant difference (P>0.05); effect on urinary protein:compared with the blank control group, model group,24h urinary protein contentincreased significantly (P <0.05), compared with model group, each group of24h urineprotein content was significantly reduced (P <0.05); effect on serum creatinine level:compared with the blank control group, no significant difference between the levels ofcreatinine in model group (P>0.05), compared with model group, each to creatinine levelthe drug showed no significant difference (P>0.05); effect on urea nitrogen level:compared with the blank control group, the level of urea nitrogen in model group hadsignificant difference (P <0.05), compared with model group, each medicine group ofurea nitrogen levels had no significant difference (P>0.05); the pathologic changes ofkidney of mice, Masson staining: blank control group, normal renal tissue morphology, nointerstitial fibrosis. DN model group with mesangial broadening, renal interstitial fibroustissue hyperplasia, with interstitial focal fibrosis, inflammatory cells infiltrating theoccasional Bureau interstitial edema and infiltration, rare tubular atrophy. Before theestablishment of the diabetic nephropathy model into medicine group mesangialbroadening is not obvious, slight interstitial fibrosis, rare infiltration of inflammatory cells.After model administration group showed mesangial matrix increase width, mesangialcells increased, interstitial fibrosis, inflammatory cell infiltration. Positive drug groupshowed mesangial matrix increase width, interstitial fibrosis. Combination groupmesangial broadening is not obvious, occasionally slight interstitial fibrosis, inflammatory cell infiltration. On the activity of TRX: compared with the blank control group, modelgroup, the activity of TRX had no statistical difference (P>0.05), compared with modelgroup, each group TRX activity had no significant difference (P>0.05); the expression ofTXNIP gene of mRNA: compared with the blank control group, model group, nosignificant expression of TXNIP gene difference (P>0.05), compared with model group,each group of thioredoxin interacting protein (TXNIP) gene expression in a downwardtrend, but no significant difference (P>0.05); the expression of CHOP gene of mRNA,compared with the blank control group, model group, no significant expression of CHOPgene difference (P>0.05), compared with model group, each group the expression ofCHOP gene has a downward trend, but no significant difference (P>0.05).Conclusion:enema prescription No.1can reduce the DN mouse model of24h urineprotein content; can improve the DN of mouse renal interstitial fibrosis, inflammatory cellinfiltration decreased; enema number one side effect on renal function in mice withdiabetic nephropathy may not be expressed by TXNIP and CHOP gene, the mechanismstill need to study further in a subsequent experiment in. |
PDF Full Text Request